{"schema_version":"secwatch.filing_event.v1","accession":"0001472375-26-000113","form_type":"8-K","ticker":"RGPX","cik":"0001357878","company_name":"REGENEREX PHARMA, INC.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.186480+00:00","generated_at":"2026-05-15T07:49:11.594565+00:00","sec_items":[],"event_type":"leadership","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Regenerex Pharma suspends CFO Kenneth Perry; appoints Don E. Ray as interim CFO","bullets":["CFO Kenneth Perry placed on administrative suspension leave with pay, effective March 31, 2026, due to concerns over compliance, financial oversight, governance, and internal controls.","Don E. Ray appointed Interim CFO effective April 1, 2026, for an initial 90-day term at an annual salary of $150,000.","Board reassigned Perry's duties to interim CFO; review of the concerns is ongoing with no final determinations yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001472375-26-000113","json":"https://secwatch.observer/filing/0001472375-26-000113.json","markdown":"https://secwatch.observer/filing/0001472375-26-000113.md","text":"https://secwatch.observer/filing/0001472375-26-000113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357878/000147237526000113/0001472375-26-000113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357878/000147237526000113/ixform8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:49:11.594565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}